Rubicon Research: FY26 profit up 84% and ₹1.50 dividend in 2026

Stock snapshot and what moved today

Rubicon Research shares were quoted at ₹1,617.95, down ₹4.05 (-0.25%) on BSE at 04:01 PM. Another market snapshot in the data shows the stock at ₹1,655.10, up ₹58.80 (+3.68%) at close (3:29:54 PM IST), indicating different time stamps or feeds. The company was also shown trading at ₹1,624.20 on Fri Aug 14, 2026 08:04:19. For investors tracking the stock around results day, these prints matter because the company has multiple scheduled events on August 14 and later in the month.

Company profile and operating focus

Rubicon Research Limited is headquartered in Mumbai, Maharashtra, and is promoted by Dr. Pratibha Pilgaonkar. It operates as a specialty pharmaceutical company focused on complex oral solid, liquid, ophthalmic, and injectable formulations. The company positions itself in pharmaceutical product innovation and development, which typically involves regulatory timelines and portfolio-led growth.

AGM on August 26: dividend and merger proposal

Rubicon Research has convened its 27th Annual General Meeting (AGM) for Wednesday, August 26, 2026 at 1:00 PM IST, to be held via video conferencing. The key shareholder approvals sought include a final dividend of ₹1.50 per equity share and the merger of its wholly owned subsidiary, KIA Health Tech Private Limited.

The board recommended the dividend based on a consolidated profit after tax (PAT) of ₹2,467 million, which is ₹246.7 crore, for the financial year ended March 31, 2026. The agenda signals that FY26 performance is being used to support shareholder payouts, while the group structure may be simplified through the proposed merger.

Earnings conference call scheduled for August 14

Rubicon Research has also scheduled a Q1FY27 earnings conference call on August 14, 2026 at 6:00 PM IST to discuss financial results for the quarter ended June 30, 2026. The call is set to include senior management, including the CEO, Mr. Parag Sancheti, and the company’s CFO (name not provided in the data).

Dial-in access is available through +91 22 6280 1149 / +91 22 7115 8050, along with international toll-free lines for USA, UK, Singapore, and Hong Kong. The company also flagged an express login option via Diamond Pass for participants.

Recent quarterly financial trend (three quarters)

The latest quarterly table in the data shows operating performance across Sep 2025, Dec 2025, and Mar 2026. Net sales moved from ₹336.47 crore in Sep 2025 to ₹301.71 crore in Dec 2025, before rising to ₹389.88 crore in Mar 2026. Operating profit rose to ₹106.17 crore in Mar 2026 from ₹79.10 crore in Sep 2025.

FY26 performance: revenue and profit expansion

For the full year ended March 31, 2026 (FY26), the company reported net profit of ₹2.47 billion (₹247 crore) and revenue of ₹17.54 billion (₹1,754 crore). The same dataset compares FY25 at net profit ₹1.34 billion (₹134 crore) and revenue ₹12.84 billion (₹1,284 crore), indicating year-on-year growth of 83.6% in net profit and 36.6% in revenue.

The company also reported Q4FY26 net profit of ₹768 million (₹76.8 crore) versus ₹362 million (₹36.2 crore) in the corresponding period, and Q4FY26 revenue of ₹5.14 billion (₹514 crore) versus ₹3.58 billion (₹358 crore).

Valuation metrics and peer context

Two valuation snapshots appear in the provided data. One states Rubicon Research has a TTM P/E of 50.14, compared with the sector P/E of 33.00. Another snapshot lists P/E 105.5 at a price point of ₹1,610, along with a market cap display of ₹26.0K crore.

Market capitalisation is also explicitly mentioned as ₹26,801.27122428 crore, calculated based on the latest share price in that feed. Listed peers referenced include Sun Pharmaceutical Industries, Divi’s Laboratories, and Torrent Pharmaceuticals, with their respective daily moves shown in the dataset.

Board meeting calendar and investor event cues

The company’s board meeting schedule listed in the data includes results and audited accounts dates. These dates often serve as catalysts for disclosures on financial performance and corporate actions.

ESOP scheme and capital deployment note

The board approved the Employees Stock Option Scheme 2026, authorising 24,84,415 options (equal number of equity shares of face value ₹1 each) for eligible employees of the company and its subsidiaries. The approval date cited is May 29, 2026, and the scheme is subject to shareholder and other regulatory approvals.

Separately, the dataset notes Rubicon Research raised around ₹161 crore through its IPO, with approximately ₹100 crore still unutilised as of May 2026. It also states that no specific new acquisitions or fundraising plans for FY2027 have been disclosed, with management indicating it would announce only when certainty exists.

What analysts are watching for Q1FY27

A preview in the data provides a trailing-growth based estimate for Q1 FY27, built on a Q1 FY26 base of ₹353 crore revenue and ₹43 crore net profit. The estimate range is ₹473-545 crore revenue and ₹57-73 crore PAT for Q1 FY27, and it cites a 12-month target range of ₹1,654-1,833 in that framework. It also notes a results timing window of July-August 2026 as indicative, aligning with the broader results season.

Conclusion

Rubicon Research is entering a busy stretch with Q1FY27 results discussion on August 14, 2026, followed by its AGM on August 26, 2026 to vote on a ₹1.50 final dividend and a proposed subsidiary merger. With FY26 showing higher revenue and profit in the company’s disclosures, the next immediate checkpoint for markets is management commentary on the August 14 earnings call and the outcomes proposed at the AGM.